pLOG

2026-04-07

Incorporating Specially Approved Manufactured or Imported Drugs into the Relief System: Analyzing the Profound Significance of the Drug Injury Relief Act Amendments for Physician-Patient Relationships

In modern medicine, drug therapy is a "double-edged sword," where efficacy and risk often coexist. With the third reading and passage of the amendments to Articles 3 and 28 of the Drug Injury Relief Act by the Legislative Yuan on January 30, 2024, "specially approved drugs for manufacture or import" have been officially incorporated into the relief system. This regulatory advancement not only fills a gap in the social safety net but also reconstructs a bridge based on trust and security for both physicians and patients at the clinical frontline.

Author: Patty Feng, Director of the Compliance Center at PatientsForce
 

Eliminating the "Moral Shackles" of Clinical Decision-Making

For a long time, when domestic drug shortages occurred or when specially approved drugs—not yet officially licensed in the country—were introduced for rare diseases or emergency medical needs, physicians, patients, and pharmacists often found themselves in a regulatory vacuum.

Unleashing Professional Choices for Physicians: In the past, when recommending the use of specially approved drugs, physicians had to weigh clinical evidence-based medicine (EBM) against the psychological burden and legal risk of knowing that "should severe side effects occur, patients would have no recourse for relief." Following the regulatory amendment, the system officially serves as the backbone for medical decisions, allowing physicians to return to pure professional judgment without resorting to "defensive medicine" out of fear of systemic deficiencies.

Implementing Equality in the Right to Life for Patients: For patients, the value of life remains equal regardless of whether they are using conventional medications or life-saving, specially approved drugs. This amendment eliminates "relief discrimination" based on a drug's regulatory status, ensuring that every user who encounters unforeseen drug injuries can receive state economic compensation and medical support.

 

Shifting from "Litigation Confrontation" to a "Risk-Sharing Community"

The breakdown of the physician-patient relationship often stems from the ambiguity of liability and the heavy financial pressure that follows an injury. The essence of the drug injury relief system is the concept of "no-fault liability" social insurance, and the buffering effect brought by its amendment is crucial:

  1. Reducing Incentives for Conflict: Timely relief payments can alleviate the urgent financial needs of affected families, effectively reducing the motivation to turn unfortunate events into medical litigation.
  2. Role Transformation: Physicians transition from being potential "defendants" to becoming "professional partners who assist patients in applying for relief." By helping collect clinical data and reporting side effects, healthcare providers and patients can stand on the same side, jointly confronting the challenges brought by pharmaceutical uncertainty.

 

Strengthening the National Pharmacovigilance Network

From the perspective of Pharmacovigilance, incorporating specially imported drugs into the relief system creates a positive cycle for data collection:

  • Improving Reporting Proactivity: In the past, due to the lack of relief incentives, side effect reports for specially approved drugs were often missed. Now, with the implementation of relief rights, clinical reporting will become increasingly accurate.
  • Building a Localized Database: This data will serve as a vital indicator for assessing the safety of special drugs in Taiwan, forming a defensive framework of “early warning, timely relief, and optimized medication use.”

The amendment of the Drug Injury Relief Act is more than just a cold change in legal clauses; it is a profound demonstration of respect for the essence of medical care. When the legal system can steadily catch the uncertainties inherent in the medical process, physicians feel empowered to push the boundaries of treatment, and patients feel secure in entrusting their lives to others. The refinement of this safety net symbolizes a critical step for Taiwan's medical environment toward a more civilized and resilient future.。